Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy Beagles

View through CrossRef
Abstract Objectives To determine bioavailability and pharmacokinetic parameters for allopurinol and its active metabolite, oxypurinol. Animals 6 healthy, reproductively intact female Beagles, 4.9 to 5.2 years old, and weighing 9.5 to 11.5 kg. Procedure In the first part of the study, allopurinol was administered IV at a dosage of 10 mg/kg of body weight to 3 dogs and 5 mg/kg to 3 dogs; the sequence was then reversed. In the second part of the study, allopurinol was administered orally at a dosage of 15 mg/kg to 3 dogs and 7.5 mg/kg to 3 dogs; the sequence was then reversed. In the third part of the study, allopurinol was administered IV (10 mg/kg), orally (15 mg/kg) with food, and orally (15 mg/kg) without food. Plasma samples were obtained at timed intervals, and concentrations of allopurinol and oxypurinol were determined. Results Maximal plasma allopurinol concentration and area under plasma allopurinol and oxypurinol concentration-time curves were 2 times greater when dogs were given 10 mg of allopurinol/kg IV, compared with 5 mg/kg, and when dogs were given 15 mg of allopurinol/kg orally, compared with 7.5 mg/kg. Allopurinol elimination half-life, time to reach maximal plasma oxypurinol concentration, and oxypurinol elimination half-life were significantly greater when dogs received 10 mg of allopurinol/kg IV, compared with 5 mg/kg, and when dogs received 15 mg of allopurinol/kg orally, compared with 7.5 mg/kg. Conclusions Elimination of allopurinol is dependent on nonlinear enzyme kinetics. The bioavailability of allopurinol, and pharmacokinetic parameters of allopurinol and oxypurinol after oral administration of allopurinol, are not affected by administration with food. Clinical Relevance A dose threshold exists beyond which additional allopurinol would not substantially further inhibit xanthine oxidase activity. Oral administration of > 15 mg of allopurinol/kg to dogs would not be expected to result in greater reduction of plasma and urine uric acid concentrations. Also, allopurinol may be administered to dogs for dissolution or prevention of urate uroliths without regard to time of feeding. (Am J Vet Res 1997;58:504–510)
Title: Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy Beagles
Description:
Abstract Objectives To determine bioavailability and pharmacokinetic parameters for allopurinol and its active metabolite, oxypurinol.
Animals 6 healthy, reproductively intact female Beagles, 4.
9 to 5.
2 years old, and weighing 9.
5 to 11.
5 kg.
Procedure In the first part of the study, allopurinol was administered IV at a dosage of 10 mg/kg of body weight to 3 dogs and 5 mg/kg to 3 dogs; the sequence was then reversed.
In the second part of the study, allopurinol was administered orally at a dosage of 15 mg/kg to 3 dogs and 7.
5 mg/kg to 3 dogs; the sequence was then reversed.
In the third part of the study, allopurinol was administered IV (10 mg/kg), orally (15 mg/kg) with food, and orally (15 mg/kg) without food.
Plasma samples were obtained at timed intervals, and concentrations of allopurinol and oxypurinol were determined.
Results Maximal plasma allopurinol concentration and area under plasma allopurinol and oxypurinol concentration-time curves were 2 times greater when dogs were given 10 mg of allopurinol/kg IV, compared with 5 mg/kg, and when dogs were given 15 mg of allopurinol/kg orally, compared with 7.
5 mg/kg.
Allopurinol elimination half-life, time to reach maximal plasma oxypurinol concentration, and oxypurinol elimination half-life were significantly greater when dogs received 10 mg of allopurinol/kg IV, compared with 5 mg/kg, and when dogs received 15 mg of allopurinol/kg orally, compared with 7.
5 mg/kg.
Conclusions Elimination of allopurinol is dependent on nonlinear enzyme kinetics.
The bioavailability of allopurinol, and pharmacokinetic parameters of allopurinol and oxypurinol after oral administration of allopurinol, are not affected by administration with food.
Clinical Relevance A dose threshold exists beyond which additional allopurinol would not substantially further inhibit xanthine oxidase activity.
Oral administration of > 15 mg of allopurinol/kg to dogs would not be expected to result in greater reduction of plasma and urine uric acid concentrations.
Also, allopurinol may be administered to dogs for dissolution or prevention of urate uroliths without regard to time of feeding.
(Am J Vet Res 1997;58:504–510).

Related Results

Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study
Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study
Objective: To examine whether allopurinol is associated with any alteration in mortality and hospitalisations in patients with chronic heart failure (CHF). This hypothesis is based...
SOME CHARACTERISTICS OF FISH SCALE COLLAGEN/ALLOPURINOL BIOCOMPOSITE
SOME CHARACTERISTICS OF FISH SCALE COLLAGEN/ALLOPURINOL BIOCOMPOSITE
In this work, collagen extracted from fresh-water fish scales has been used as a matrix in the drug delivery polymeric system. Allopurinol has been applied to reduce the concentrat...
Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy Beagles
Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy Beagles
Abstract Objectives To determine whether diet influences the metabolism of IV administered allopurinol in healthy dogs. Animals 6 healthy female Beagles, 4.9 to 5.2 years old an...
Complex interaction between allopurinol-induced uric acid reduction and glycemic control: a clinical and molecular study
Complex interaction between allopurinol-induced uric acid reduction and glycemic control: a clinical and molecular study
Background: Diabetes mellitus type 2 (DMT2) and hyperuricemia are two prevalent metabolic diseases worldwide, including in Indonesia. In fact, in the Minahasa tribe, the prevalence...
Influence of allopurinol on thiopurine associated toxicity: A retrospective population‐based cohort study
Influence of allopurinol on thiopurine associated toxicity: A retrospective population‐based cohort study
AimsThiopurines are important for treating inflammatory bowel disease, but are often discontinued due to adverse effects. Concomitant use of allopurinol might lower the risk of the...
Multicentre study and systematic review: Allopurinol exposure during pregnancy
Multicentre study and systematic review: Allopurinol exposure during pregnancy
SummaryBackgroundData about the safety of allopurinol in pregnant women are sparsely reported.AimsTo investigate the risk of adverse pregnancy outcome and congenital abnormalities ...
Population Pharmacokinetics of Rifampicin on Pulmonary Tuberculosis Patients
Population Pharmacokinetics of Rifampicin on Pulmonary Tuberculosis Patients
Abstract: This study aimed to establish a reasonable population pharmacokinetic model for rifampicin taken orally by patients with pulmonary tuberculosis, estimate pharmacokinetic ...
Ophthalmopathies in Dogs with Visceral Leishmaniasis - Treatment with Allopurinol and Diagnosis by qPCR and Cytology
Ophthalmopathies in Dogs with Visceral Leishmaniasis - Treatment with Allopurinol and Diagnosis by qPCR and Cytology
Background: Canine visceral leishmaniasis (CVL) is an infectious parasitic zoonotic disease endemic to several countries. Among the most common clinical symptoms of CVL are eye sym...

Back to Top